Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

NCT04578496 is registered in ClinicalTrials.gov with Clinuvel Pharmaceuticals Limited as lead sponsor.

NCT NCT04578496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04578496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Lead sponsor
Clinuvel Pharmaceuticals Limited
Phase
Phase 3
Overall status
Completed
Start date
July 11, 2011
Completion date
February 27, 2014
Enrollment
16 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria